Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.01
Bid: 1.84
Ask: 1.96
Change: -0.14 (-6.86%)
Spread: 0.12 (6.522%)
Open: 2.00
High: 2.01
Low: 2.00
Prev. Close: 2.04
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK EARNINGS SUMMARY: Itaconix 2019 Loss Narrows On Strong Revenue Rise

Wed, 30th Sep 2020 18:37

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Itaconix PLC - chemicals company - For 2019, pretax loss narrowed to USD1.4 million from USD10.1 million the year before, on revenue that grew by 46% to USD1.3 million from USD881,000, as a result of increased product demand, cost savings and new orders from customers in Europe.

----------

New Trend Lifestyle Group PLC - Singapore-based Feng Shui products maker - For first half of 2020, pretax loss widens to SGD1.4 million from SGD314,000 the year before, on revenue that fell by 38% to SGD1.9 million from SGD3.1 million, as retail outlets were closed due to lockdown restrictions.

----------

Immupharma PLC - pharmaceutical company - For the first half of 2020, pretax loss narrows to GBP3.1 million from GBP6.7 million the year before, on revenue that dropped to GBP62,207 from GBP77,925.

----------

Echo Energy PLC - Latin American-focused upstream oil and gas firm - For the first half of 2020, pretax loss narrows to USD5.7 million from USD7.9 million, on revenue that more than doubled to USD5.7 million from USD2.7 million, on production that came up to 390,844 barrels of oil equivalent.

----------

Goldstone Resources Ltd - Africa-focused gold resource developer - For the first half of 2020, pretax loss widens to USD292,098 from USD289,951 the year before, despite a fall in administrative expenses. During period, gained formal approval for ten-year mining lease on Akrokeri and Homase licences in Ghana.

----------

Quixant PLC - Cambridge-based technology outsourcer for gaming industry - For first half of 2020, swings to pretax loss of GBP3.0 million from profit of USD3.0 million the year before. On adjusted basis, pretax loss at USD1.4 million from profit of USD3.4 million, on revenue that declined to USD27.9 million from USD41.9 million. Looking ahead, expects return to profitable trading in second half of year.

----------

Aberdeen Standard European Logistics Income PLC - Investment trust - As at June 30, net asset value per share at EUR1.13 compared to EUR1.11 on December 31.

----------

Schroder UK Public Private Trust PLC - investment trust - As at June 30, net asset value per share fell 8.1% to 45.44 pence from 49.46p at the end of December 31.

----------

Trident Royalties PLC - London-based mining royalty firm - For the first half of 2020, pretax loss widens to USD1.1 million from USD138,844 the year before. Looking ahead, commodity markets have continued to strengthen in the third quarter, leading to a positive outlook for the rest of the year.

----------

Hemogenyx Pharmaceuticals PLC - pre-clinical stage biopharmaceutical firm headquartered in London - For the first half of 2020, pretax loss widens to GBP835,189 from GBP706,670 the year before due to rise in administrative costs. Keeps confident outlook due to significant progress on several development fronts, including CDX antibody research.

----------

Immotion Group PLC - immersive entertainment company headquartered in Manchester - For the first half of 2020, pretax loss remains flat at GBP2.6 million, on revenue that dropped to GBP818,000 from GBP1.3 million the year before, due to four months of trading being effectively lost to the Covid-19 lockdown.

----------

India Capital Growth Fund Ltd - investment fund - As at June 30, net asset value per share down 20% to 70.42 pence from 97.02p the same date the year before. Portfolio holds 32 investee companies, as seven holdings were sold and seven new investments were made.

----------

Chesterfield Resources PLC - copper-gold exploration and development company active in Cyprus - For the first half of 2020, pretax loss narrows to GBP257,465 from GBP303,704 the year before. Looking ahead, outlook for copper and gold is robust, as commodities rose following lockdowns.

----------

URU Metals Ltd - exploration and development - For the year to the end of March, pretax loss narrows to USD732,000 from USD2.3 million due to the absence of exceptional charges related to the impairment of group's 50% interest in the Burgersfort project and shares held in Management Resource Solutions PLC.

----------

Edenville Energy PLC - operator of the Rukwa coal project in southwest Tanzania - For 2019, pretax loss widens to GBP1.9 million from GBP1.8 million, as revenue declined to GBP233,414 from GBP337,125. The lack of capital following debt repayments in Tanzania affected the company's ability to increase production to targeted levels.

----------

ADM Energy PLC - natural resources investor with assets in Nigeria - For the first half of 2020, pretax loss widens to GBP975,000 from GBP448,000, due to no revenue being made for period, compared to GBP2.2 million the prior year. Total production from Aje field was 2,126 barrels of oil per day, down from 2,967 bopd.

----------

SEEEN PLC - London-based social media technology firm - For the first half of 2020, pretax loss widens to USD2.0 million from USD219,572 the year before on sharp rise in administrative expenses, despite generating revenue of USD3.7 million. For the third quarter, revenue improved as viewer growth accelerated.

----------

Predator Oil & Gas Holdings PLC - Jersey-based oil and gas company - For the first half of 2020, pretax loss widened to GBP784,156 from GBP512,263 the year before, as no revenue generated. Successfully executed phases one and two of Pilot Enhanced Oil Recovery onshore Trinidad using injected carbon dioxide.

----------

Solo Oil PLC - AIM-listed oil investment company - For the first half of 2020, pretax loss was GBP1.3 million, widened from GBP800,000. During period, did not proceed with acquisition of offshore Netherlands assets from ONE Dyas. Is continuing to screen acquisition opportunities.

----------

Triple Point Social Housing REIT PLC - London-based real estate investment trust - As at June 30, net asset value per share is up at 105.34 pence from 103.96p the year before. For the six month-period, annualised rental income rose to GBP28.0 million from GBP21.1 million. However, pretax profit dropped to GBP9.0 million from GBP9.9 million. Dividend per share up at 2.59 pence from 2.54p. Plans to raise GBP70 million through a placing, open offer and subscription of shares at price of 106 pence each.

----------

Open Orphan PLC - pharmaceutical services company - For the first half of 2020, pretax loss widens to GBP6.8 million from GBP1.1 million, despite generating revenue of GBP7.1 million.

----------

Provexis PLC - health food ingredient maker - For the year to the end of March, pretax loss narrows to GBP424,465 from GBP533,375, on revenue that rose by 8% to GBP347,937 from GBP322,189 the year before, through high product sales.

----------

SIMEC Atlantis Energy Ltd - London-based developer of renewable and sustainable energy projects - For the first half of 2020, pretax loss narrows to GBP6.2 million from GBP12.4 million the year before, as revenue rose sharply to GBP7.9 million from GBP2.0 million, from contributions generated by the Atlantis tidal turbine and engineering services division.

----------

Trafalgar Property Group PLC - residential homes developer based in Kent - For the year to the end of March, pretax loss narrows to GBP1.0 million from GBP2.3 million, due to a smaller writing off of assets. Revenue dipped to GBP2.0 million from GBP2.1 million, reflecting the sale of two assets, compared to five assets the prior year.

----------

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
14 Sep 2022 12:46

IN BRIEF: ImmuPharma receives response for FDA for Lupuzor

ImmuPharma PLC - specialist drug discovery and development company - Says its US partner for Lupuzor, Avion Pharmaceuticals LLC, has received a written response from the US Food & Drug Administration that provided detailed guidance on the next steps for the drug's clinical programme. This included advice on the dosing regime, as well as guidance on the study protocol that can be amended to improve the regulatory outcome.

Read more
7 Sep 2022 09:55

ImmuPharma raises GBP150,000 via issue of 3 million new shares

ImmuPharma PLC - specialist drug discovery and development company - Says L1 Capital Global Opportunities Master Fund has exercised options over 3.0 million new shares at a price of 5 pence each, for GBP150,000 in total. The new shares represent 0.9% of the company's enlarged share capital.

Read more
31 Aug 2022 21:41

TRADING UPDATES: ImmuPharma waits on FDA; IDE Group waits on audit

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
11 Aug 2022 19:08

IN BRIEF: ImmuPharma raises GBP950,000 from broker option

ImmuPharma PLC - specialist drug discovery and development company - Raises GBP950,000 under broker option, taking total proceeds from placing and broker option to GBP1.04 million. "Further to the announcement of August 3, 2022, the directors confirm that the fundraising, together with existing funding and funding arrangements, will provide the company with sufficient working capital for at least the next 12 months," it says.

Read more
3 Aug 2022 19:40

IN BRIEF: ImmuPharma to raise funds for investment into pipeline

ImmuPharma PLC - specialist drug discovery and development company - Intends to raise GBP1.1 million through the placing and subscription of 21.8 million shares at a price of 5.0 pence per share.

Read more
7 Jul 2022 20:35

IN BRIEF: ImmuPharma US partner gets Type C meeting with US FDA

ImmuPharma PLC - specialist drug discovery and development company - Says Avion Pharmaceuticals, its US partner for its Lupuzor lupus treatment, received a Type C Meeting confirmation from the US Food & Drug Administration. The London-listed company says statement of purpose, objectives and proposed agenda of the meeting have already been agreed on, as has the option to provide written responses, rather than face-to-face meetings. The FDA has agreed to provide a written response by August 29.

Read more
21 Jun 2022 16:05

UK shareholder meetings calendar - next 7 days

Wednesday 22 June 
ASA International Group PLCAGM
Atalaya Mining PLCAGM
Bonhill Group PLCAGM
Chapel Down Group PLCAGM
Churchill China PLCAGM
Downing Renewables & Infrastructure Trust PLCGM re share issue
Ecofin US Renewables Infrastructure Trust PLCAGM
EJF Investments LtdAGM
Frenkel Topping Group PLCAGM
Good Energy Group PLCAGM
Honeycomb Investment Trust PLCAGM
ICG-Longbow Senior Secured UK Property Debt Investments LtdAGM
Intelligent Ultrasound Group PLCAGM
Iofina PLCAGM
John Wood Group PLCAGM
Kingfisher PLCAGM
LXi REIT PLCGM
Menhaden PLCAGM
North Atlantic Smaller Cos Investment Trust PLCAGM
Pennant International Group PLCAGM
Plant Health Care PLCAGM
Skillcast Group PLCAGM
Team PLCAGM
Tribal Group PLCGM re final dividend
Trident Royalties PLCAGM
Vertu Motors PLCAGM
Wentworth Resources PLCAGM
Thursday 23 June 
Avacta Group PLCAGM
Anglo Asian Mining PLCAGM
Card Factory PLCAGM
Cordiant Digital Infrastructure LtdAGM
Downing Renewables & Infrastructure Trust PLCGM re initial placing & open offer
Eight Capital Partners PLCGM re aligning 2022 bonds with 2026 bonds
GENinCode PLCAGM
Ideagen PLCGM re takeover by Hg Pooled Management Ltd
Longboat Energy PLCAGM
Oxford Nanopore Technologies PLCAGM
Puma VCT 13 PLCGM re cancellation of listing & liquidation
RBG Holdings PLCAGM
Tandem Group PLCAGM
Union Jack Oil PLCAGM
Zinnwald Lithium PLCAGM
Friday 24 June 
AFC Energy PLCGM re fees for non-executive directors
Avast PLCAGM
Devolver Digital IncAGM
Entain PLCAGM
Gulf Keystone Petroleum LtdAGM
Hawkwing PLCAGM
Invesco Bond Income Plus LtdAGM
Life Science REITAGM
Northcoders Group PLCAGM
Princess Private Equity Holding LtdAGM
Monday 27 June 
Anglo-Eastern Plantations PLCAGM
Celadon Pharmaceuticals PLCAGM
Cizzle Biotechnology Holdings PLCAGM
Echo Energy PLCAGM
Medica Group PLCAGM
Pelatro PLCAGM
Surgical Innovations Group PLCAGM
Warpaint London PLCAGM
Tuesday 28 June 
4D Pharma PLCAGM
Acceler8 Ventures PLCAGM
Airtel Africa PLCAGM
Alina Holdings PLCAGM
Aquila Energy Efficiency Trust PLCAGM
Attraqt Group PLCAGM
Bay Capital PLCAGM
Capital & Counties Properties PLCAGM
CMO Group PLCAGM
Corre Energy BVAGM
Creo Medical Group PLCAGM
Futura Medical PLCAGM
Gama Aviation PLCAGM
ICG Enterprise Trust PLCAGM
ImmuPharma PLCAGM
IQE PLCAGM
Katoro Gold PLCAGM
Rockhopper Exploration PLCAGM
Sound Energy PLCAGM
TP Group PLCAGM
UK Oil & Gas PLCAGM
Volvere PLCAGM
Zegona Communications PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
25 May 2022 16:53

IN BRIEF: ImmuPharma shares fall as annual loss widens

ImmuPharma PLC - specialist drug discovery and development company - Widens its pretax loss to GBP8.9 million in 2021 from GBP7.2 million loss the previous year. Loss includes exceptional costs in respect of corporate reorganisation and respective settlement arrangements, company adds. Revenue drops 6.6% to GBP118,350 from GBP126,667. Research and development expenses surge to GBP3.7 million from GBP2.4 million. P140-related expenditure was the main reason for this increase. P140, also known as Llupuzor, is a potential treatment for Lupus. Company does not propose a dividend.

Read more
6 May 2022 19:11

TRADING UPDATES: Enwell pleased with SV-31; SDX Energy ties in well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
4 May 2022 13:03

ImmuPharma making final preparations for Lupuzor phase 3 trial

(Sharecast News) - Specialist drug discovery and development company ImmuPharma said on Wednesday that final preparations were now underway to progress 'Lupuzor' into its new, optimised international phase 3 trial in lupus patients.

Read more
13 Apr 2022 13:54

ImmuPharma surges on success in latest trial of lupus treatment

(Sharecast News) - Specialist drug discovery and development company ImmuPharma reported positive data from its 'Lupuzor' pharmacokinetic study on Wednesday, as part of the new, optimised international third phase trial in lupus patients.

Read more
13 Apr 2022 12:09

IN BRIEF: Immupharma shares soar on positive data from lupus study

Immupharma PLC - London-based drug discovery and development company - Says its Lupuzor/P140 pharmacokinetic study, required by the US Food & Drug Administration, has met the key endpoints requested. The study is part of an international phase 3 trial of the Lupuzor treatment for patients with lupus disease. The dosing of healthy subjects started on February 15 and showed that P140 was safe and well-tolerated across all doses and in all subjects. Notes that the positive data now clears the path for the start of all clinical studies within the P140 platform. Adds that there is a planned Phase 2a/3 pivotal trial in chronic inflammatory demyelinating polyneuropathy, a rare neurological disorder.

Read more
13 Apr 2022 11:06

AIM WINNERS & LOSERS: ImmuPharma hits milestone; Shearwater contract

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
7 Feb 2022 18:29

TRADING UPDATES: Alphawave teams with Intel; Cadence's Amapa progress

TRADING UPDATES: Alphawave teams with Intel; Cadence's Amapa progress

Read more
7 Feb 2022 13:13

ImmuPharma updates plan for trials of lupus treatment Lupuzor

(Sharecast News) - Drug discovery and development specialist ImmuPharma updated the market on the pharmacokinetic study of 'Lupuzor' on Monday, as part of the new, optimised international phase 3 trial of Lupuzor in lupus patients.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.